Inclisiran: a small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemia.

Abstract

INTRODUCTION:

Inclisiran is a novel posttranscriptional gene silencing therapy that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) synthesis by RNA interference and has a potent, dose-dependent, durable effect in lowering LDL-C, and therefore is an effective drug to treat dyslipidemia, reducing the risk for acute cardiovascular (CV) events. It is safe and well-tolerated.

AREAS COVERED:

This paper aims to review the mechanism of action of inclisiran while evaluating its efficacy and safety in the treatment of dyslipidemia from data of the clinical trials in the ORION program.

EXPERT OPINION:

Data from the clinical trials in the ORION program demonstrated efficacy and safety of inclisiran in patients with dyslipidemia. Adverse events were similar in the inclisiran and placebo groups in the clinical trials, although injection-site reactions were more frequent with inclisiran than with placebo. Although the combination of efficacy and safety makes inclisiran a good option for the treatment of dyslipidemia compared to other PCSK9 targeting therapeutic strategies, however, further studies should exclude the possibility that inclisiran, through lower-affinity interactions, may influence other mRNAs in the physiological milieu.

• Authors: Yajnavalka Banerjee, Anca Pantea Stoian, Arrigo Francesco Giuseppe Cicero, Federica Fogacci, Dragana Nikolic, Alexandros Sachinidis, Ali A Rizvi, Andrej Janez, Manfredi Rizzo
• Journal: Expert opinion on drug safety (Expert Opin Drug Saf) Vol. 21 Issue 1 Pg. 9-20 (Jan 2022) ISSN: 1744-764X [Electronic] England
• PMID: 34596005 (Publication Type: Journal Article, Review)

Chemical References

• ALN-PCS
• RNA, Small Interfering
• PCSK9 protein, human
• Proprotein Convertase 9

Topics

• Animals
• Cardiovascular Diseases (etiology, prevention & control)
• Dyslipidemias (genetics, therapy)
• Gene Silencing
• Humans
• Hypercholesterolemia (genetics, therapy)
• Proprotein Convertase 9 (genetics)
• RNA, Small Interfering (administration & dosage, adverse effects)